Study to Assess Efficacy, Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine at Different Viral Concentrations in Healthy Infants Previously Uninfected With Human Rotavirus and Approximately 3 Months of Age
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2016
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 13 Apr 2007 The expected completion date for this trial is now 15 Apr 2003.
- 05 Mar 2007 New trial record.